Academic Journal

Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing
Συγγραφείς: Roni Sverdlov Arzi, Asaf Kay, Yulia Raychman, Alejandro Sosnik
Πηγή: Pharmaceutics, Vol 13, Iss 529, p 529 (2021)
Στοιχεία εκδότη: MDPI AG
Έτος έκδοσης: 2021
Συλλογή: Directory of Open Access Journals: DOAJ Articles
Θεματικοί όροι: kinase inhibitors, pure drug nanoparticles, drug nanocrystals, bottom-up nanonization, nanoprecipitation, microfluidics, Pharmacy and materia medica, RS1-441
Περιγραφή: Nanoprecipitation is one of the most versatile methods to produce pure drug nanoparticles (PDNPs) owing to the ability to optimize the properties of the product. Nevertheless, nanoprecipitation may result in broad particle size distribution, low physical stability, and batch-to-batch variability. Microfluidics has emerged as a powerful tool to produce PDNPs in a simple, reproducible, and cost-effective manner with excellent control over the nanoparticle size. In this work, we designed and fabricated T- and Y-shaped Si-made microfluidic devices and used them to produce PDNPs of three kinase inhibitors of different lipophilicity and water-solubility, namely imatinib, dasatinib and tofacitinib, without the use of colloidal stabilizers. PDNPs display hydrodynamic diameter in the 90–350 nm range as measured by dynamic light scattering and a rounded shape as visualized by high-resolution scanning electron microscopy. Powder X-ray diffraction and differential scanning calorimetry confirmed that this method results in highly amorphous nanoparticles. In addition, we show that the flow rate of solvent, the anti-solvent, and the channel geometry of the device play a key role governing the nanoparticle size.
Τύπος εγγράφου: article in journal/newspaper
Γλώσσα: English
Relation: https://www.mdpi.com/1999-4923/13/4/529; https://doaj.org/toc/1999-4923; https://doaj.org/article/42000b40b402496d9e95b5265b08ec12
DOI: 10.3390/pharmaceutics13040529
Διαθεσιμότητα: https://doi.org/10.3390/pharmaceutics13040529
https://doaj.org/article/42000b40b402496d9e95b5265b08ec12
Αριθμός Καταχώρησης: edsbas.2EF47AB9
Βάση Δεδομένων: BASE